Estrogen-induced epigenetic silencing of myotrophin reduces proliferation and is associated with chemosensitivity in hepatocellular carcinoma cells
Epigenomics · 03.04.2026 · 18 (4) · 385-396
DOI: 10.1080/17501911.2026.2654575 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epigenomics, online erschienen am 08.04.2026. Verfasst von Jibran Sualeh Muhammad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Epigenesis, Genetic, Estrogens. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: King Hussein Cancer Foundation, Jordan, NYU Abu Dhabi.
Abstract (Originalsprache)
BACKGROUND: Hepatocellular carcinoma (HCC) carries poor survival and limited response to conventional chemotherapy. Epidemiological evidence suggests a lower incidence of HCC in females, implicating estrogen (E2) in tumor suppression. The epigenetic mechanisms underlying estrogen-associated protection remain incompletely defined. RESEARCH DESIGN AND METHODS: We investigated the relationship between E2 exposure, myotrophin (MTPN) expression, and chemotherapy response using TCGA HCC datasets, human hepatoma cell lines (HepG2, HUH7), zebrafish larvae, and a diethylnitrosamine (DEN)-induced mouse model. Cells were pretreated with E2 (10 nM, 6 h) followed by doxorubicin (DOX; up to 2.0 nM, 24 h). Promoter methylation was assessed by quantitative methylation-specific PCR. Cell viability, apoptosis, DNA damage, liver size, tumor burden, and protein expression were evaluated. RESULTS: MTPN was overexpressed and hypomethylated in human HCC. E2 exposure reduced MTPN expression and increased promoter methylation in vitro and in vivo. MTPN knockdown decreased HCC cell viability and proliferation. E2 pretreatment enhanced DOX-associated apoptotic responses in hepatoma cells. In DEN-induced HCC, E2 reduced liver size, tumor burden, and hepatic MTPN protein levels. CONCLUSIONS: Estrogen-associated epigenetic repression of MTPN contributes to growth suppression in HCC and is associated with enhanced cytotoxic responses to DOX. Clinical validation is required to determine prognostic or therapeutic relevance. Liver cancer, also called hepatocellular carcinoma (HCC), is one of the leading causes of cancer-related death worldwide. Current treatments often do not work well, and many patients develop resistance to chemotherapy. Interestingly, liver cancer occurs less often in women than in men, suggesting that female hormones such as estrogen may offer some protection. In this study, we examined how estrogen affects liver cancer cells and whether it can improve the response to chemotherapy. We focused on a gene called myotrophin (MTPN), which is found at higher levels in liver cancer tissue compared with normal liver. Using patient data and laboratory models–including human liver cancer cells, zebrafish, and mice–we found that estrogen reduces the activity of this gene. Estrogen also changed chemical marks on DNA that control whether the gene is switched on or off. When MTPN levels were reduced, liver cancer cells grew more slowly. Estrogen treatment also increased the cancer cells’ response to a chemotherapy drug called doxorubicin. These findings suggest that targeting MTPN or related pathways may help improve liver cancer treatment. Further clinical studies are needed to confirm these results in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
- College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
- Program in Biology, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.
- Center for Genomics and Systems Biology, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.
- Department of Medical Laboratory Sciences, College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
Förderung
- King Hussein Cancer Foundation, Jordan
- NYU Abu Dhabi
Zitieren
APA
Muhammad, J. S., Rah, B., Khan, N., Janeeh, A., Shafarin, J., Talaat, I., Sadler, K. C., & Hamad, M. (2026). Estrogen-induced epigenetic silencing of myotrophin reduces proliferation and is associated with chemosensitivity in hepatocellular carcinoma cells. Epigenomics, 18(4), 385-396. https://doi.org/10.1080/17501911.2026.2654575
Vancouver
Muhammad JS, Rah B, Khan N, Janeeh A, Shafarin J, Talaat I, et al. Estrogen-induced epigenetic silencing of myotrophin reduces proliferation and is associated with chemosensitivity in hepatocellular carcinoma cells. Epigenomics. 2026;18(4):385-396. doi:10.1080/17501911.2026.2654575
BibTeX
@article{Muhammad2026,
author = {Muhammad, Jibran Sualeh and Rah, Bilal and Khan, Nouf and Janeeh, Aisha and Shafarin, Jasmin and Talaat, Iman and Sadler, Kirsten C and Hamad, Mawieh},
title = {Estrogen-induced epigenetic silencing of myotrophin reduces proliferation and is associated with chemosensitivity in hepatocellular carcinoma cells},
journal = {Epigenomics},
year = {2026},
volume = {18},
number = {4},
pages = {385--396},
doi = {10.1080/17501911.2026.2654575}
}
EUVIMED